+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Methicillin-Resistant Staphylococcus Aureus Drugs Market - Global Forecast 2026-2032- Product Image
Methicillin-Resistant Staphylococcus Aureus Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Methicillin-Resistant Staphylococcus Aureus Drugs Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968650
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Methicillin-Resistant Staphylococcus Aureus Drugs Market is projected to reach USD 2.34 Billion in 2026. It is expected to continue growing at a CAGR of 5.72%, reaching USD 3.28 Billion by 2032.

The Methicillin-Resistant Staphylococcus aureus drugs market is shaped by the persistent clinical burden of MRSA across hospitals, long-term care facilities, and community settings. MRSA remains a priority antimicrobial resistance threat because it can cause skin and soft tissue infections, pneumonia, bacteremia, endocarditis, osteomyelitis, and device-associated infections, often requiring targeted anti-MRSA antibiotics and careful antimicrobial stewardship.

Demand is anchored by evidence-based use of vancomycin, daptomycin, linezolid, ceftaroline, dalbavancin, oritavancin, tedizolid, delafloxacin, omadacycline, and related therapies depending on infection site, severity, susceptibility profile, renal function, drug interaction risk, and patient-specific factors. The market is increasingly defined by rapid diagnostics, outpatient parenteral antimicrobial therapy, hospital formulary management, infection prevention, and the urgent need to preserve antibiotic effectiveness while improving patient outcomes.

Transformative Shifts in the MRSA Treatment Landscape

The landscape for MRSA therapeutics is shifting from empiric broad-spectrum treatment toward faster pathogen identification, susceptibility-guided therapy, and stewardship-aligned prescribing. Hospitals are adopting rapid molecular tests, antimicrobial stewardship programs, decolonization protocols where appropriate, and infection-prevention measures to reduce inappropriate antibiotic exposure and improve time-to-effective therapy.

Commercial dynamics are also changing. Long-acting lipoglycopeptides support outpatient treatment models for selected acute bacterial skin and skin structure infections, while established generic agents continue to shape pricing and access. At the same time, regulatory incentives for qualified infectious disease products, hospital reimbursement constraints, surveillance requirements, and the scientific difficulty of antibiotic discovery continue to influence pipeline investment in MRSA drugs.

Cumulative Impact of Artificial Intelligence on MRSA Drugs

Artificial intelligence is beginning to influence the MRSA drugs ecosystem by improving antimicrobial discovery workflows, resistance surveillance, clinical decision support, and diagnostic interpretation. AI models can prioritize chemical libraries, predict antimicrobial activity, analyze genomic resistance markers, and support earlier detection of outbreak patterns when integrated with verified laboratory, genomic, and epidemiological data.

The cumulative impact is practical rather than speculative: AI can shorten screening cycles, improve stewardship signals, support dose-optimization research, and strengthen real-world evidence generation, but it does not replace clinical validation, susceptibility testing, randomized trials, or regulatory review. For MRSA therapeutics, the highest-value AI use cases are those connected to curated microbiology datasets, hospital electronic health records, pharmacokinetic and pharmacodynamic evidence, and post-market safety monitoring.

Key Regional Insights Across Global MRSA Drug Demand

North America remains a major region for MRSA drugs due to advanced hospital infrastructure, strong infectious disease surveillance, and established reimbursement pathways for branded and generic antibiotics. The CDC has identified MRSA as a serious antimicrobial resistance threat in the United States, supporting continued investment in diagnostics, stewardship, and infection control. Canada follows similar stewardship priorities, with provincial programs emphasizing appropriate antibiotic use, laboratory reporting, and healthcare-associated infection prevention.

Europe is shaped by coordinated antimicrobial resistance policy, with the European Centre for Disease Prevention and Control and national agencies tracking resistant pathogens across healthcare systems. The European Union’s emphasis on AMR action plans, hospital infection prevention, pharmacovigilance, and prudent antibiotic prescribing supports structured demand for anti-MRSA agents. Asia-Pacific shows diverse conditions, with Japan, South Korea, Australia, China, India, and ASEAN markets facing different combinations of hospital capacity, generic competition, surveillance maturity, healthcare access, and stewardship implementation.

Latin America, the Middle East, and Africa present important access and stewardship considerations. Brazil and Mexico are central to Latin American demand due to large hospital networks and public-sector antibiotic procurement needs, while GCC countries in the Middle East are investing in hospital modernization, infection control, and antimicrobial stewardship frameworks. Across Africa, MRSA drug needs are influenced by diagnostic capacity, access to quality-assured antibiotics, laboratory workforce development, and strengthening surveillance aligned with global AMR priorities.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly important for MRSA drugs as hospital networks expand, medical tourism grows in selected countries, and governments strengthen antimicrobial resistance surveillance. Demand is supported by rising healthcare utilization, but access depends on affordability, diagnostic availability, procurement models, and stewardship capacity across countries with varied public and private healthcare systems.

The GCC is characterized by high investment in tertiary care, infection prevention, and imported specialty medicines, creating demand for reliable anti-MRSA therapies in hospitals. The European Union benefits from coordinated AMR policy, clinical guideline harmonization, pharmacovigilance systems, and cross-border surveillance, while BRICS countries represent large patient populations, expanding domestic pharmaceutical manufacturing, and significant need for quality-assured MRSA treatment options supported by stronger stewardship and laboratory capacity.

G7 markets shape innovation, regulatory standards, reimbursement expectations, and stewardship practices for MRSA therapeutics, including incentives for new antibiotics and evidence-based formulary decisions. NATO member countries, many of which overlap with G7 and EU systems, also prioritize resilient medical supply chains, preparedness for infectious disease threats, and continuity of essential antibiotic access, reinforcing the strategic relevance of antimicrobial availability.

Key Country Insights Shaping MRSA Therapeutics

The United States is a leading country for MRSA drugs because of high diagnostic adoption, advanced hospital stewardship programs, national AMR monitoring, and a broad portfolio of approved anti-MRSA therapies. Canada emphasizes stewardship and provincial procurement discipline, while Mexico and Brazil reflect growing demand tied to hospital infection management, public-sector purchasing, access to quality generics, and strengthening laboratory surveillance.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong hospital systems with national AMR action plans, while Russia faces the dual importance of hospital infection control and antimicrobial access. Germany and France are particularly influential in evidence-based prescribing and reimbursement assessment, Italy and Spain continue to strengthen healthcare-associated infection control, and the United Kingdom prioritizes AMR surveillance, stewardship, and national action planning through public health policy.

China and India are pivotal due to large patient bases, expanding hospital care, and substantial domestic antibiotic manufacturing, but both countries require robust stewardship to limit resistance pressure and improve appropriate antibiotic use. Japan, South Korea, and Australia are mature Asia-Pacific markets with strong regulatory oversight, hospital infection-control practices, active AMR surveillance, and demand for advanced MRSA therapies where clinically justified.

Actionable Recommendations for MRSA Drug Industry Leaders

Industry leaders should prioritize stewardship-compatible commercialization by positioning MRSA drugs around verified clinical value, susceptibility-guided use, safety, dosing convenience, resistance profile, and total cost of care. Evidence packages should include real-world outcomes, hospital length-of-stay impact, outpatient treatment feasibility, pharmacokinetic and pharmacodynamic rationale, and pharmacoeconomic data relevant to formulary committees.

Pharmaceutical developers and commercial teams should invest in differentiated mechanisms, resistance monitoring, pediatric and special-population evidence, and combination strategies where scientifically justified. Diagnostic partnerships, AI-supported surveillance, robust medical education, manufacturing continuity, and supply chain resilience should be treated as strategic capabilities rather than optional add-ons in the MRSA drugs market.

Research Methodology for MRSA Drugs Analysis

This executive summary is built on secondary research from verified public health, regulatory, scientific, and clinical sources, including WHO antimicrobial resistance publications, CDC threat assessments and treatment guidance, ECDC surveillance outputs, national AMR action plans, FDA and EMA drug approval information, peer-reviewed infectious disease literature, and recognized clinical practice guidelines.

The analysis applies triangulation across epidemiology, approved drug portfolios, regional policy frameworks, hospital stewardship trends, resistance surveillance, diagnostic adoption, and commercial access factors. Insights are limited to evidence-supported observations and avoid unverified market sizing, speculative clinical claims, unsupported performance projections, or comparative claims without a validated source base.

Conclusion on the Future of MRSA Drugs

The MRSA drugs market remains essential to global infectious disease care as antimicrobial resistance continues to challenge hospitals and communities. Established therapies remain clinically important, while newer agents, rapid diagnostics, stewardship programs, infection-prevention practices, and AI-enabled surveillance are reshaping how MRSA infections are identified and treated.

Future progress will depend on balancing innovation with responsible antibiotic use. Organizations that align drug development, access, diagnostics, evidence generation, and stewardship with verified clinical need will be best positioned in the evolving market for Methicillin-Resistant Staphylococcus aureus therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Class
7.1. Introduction
7.2. Cephalosporins
7.3. Glycopeptides
7.3.1. Teicoplanin
7.3.2. Vancomycin
7.4. Lipopeptides
7.5. Oxazolidinones
7.5.1. Linezolid
7.5.2. Tedizolid
7.6. Tetracyclines
7.6.1. Eravacycline
7.6.2. Tigecycline
8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Administration Route
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Patient Type
9.1. Introduction
9.2. Inpatient
9.3. Outpatient
10. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Clinics
11.4. Research and Academic Institutes
12. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Aridis Pharmaceuticals Inc.
16.3. Armata Pharmaceuticals, Inc.
16.4. AstraZeneca PLC
16.5. Basilea Pharmaceutica Ltd.
16.6. Bausch Health Companies Inc.
16.7. Baxter International Inc.
16.8. Becton, Dickinson and Company
16.9. Cardinal Health, Inc.
16.10. Cumberland Pharmaceuticals Inc.
16.11. Debiopharm SA
16.12. Dr. Reddy's Laboratories Ltd.
16.13. F. Hoffmann-La Roche Ltd.
16.14. Fresenius Kabi AG
16.15. GlaxoSmithKline PLC
16.16. Innovation Pharmaceuticals Inc.
16.17. Johnson & Johnson Services, Inc.
16.18. Lupin Limited
16.19. Melinta Therapeutics LLC
16.20. Merck & Co., Inc.
16.21. Nabriva Therapeutics GMBH
16.22. Novartis AG
16.23. Paratek Pharmaceuticals, Inc.
16.24. Pfizer Inc.
16.25. R-Biopharm AG
16.26. Shionogi Inc.
16.27. Takeda Pharmaceutical Company Limited
16.28. Teva Pharmaceutical Industries ltd
16.29. Theravance Biopharma, Inc.
List of Figures
FIGURE 1. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL GLYCOPEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL GLYCOPEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL GLYCOPEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL TEICOPLANIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL TEICOPLANIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL TEICOPLANIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL LIPOPEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL LIPOPEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL LIPOPEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL OXAZOLIDINONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL OXAZOLIDINONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL OXAZOLIDINONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL LINEZOLID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL LINEZOLID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL LINEZOLID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TEDIZOLID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TEDIZOLID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TEDIZOLID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL TETRACYCLINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL TETRACYCLINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL TETRACYCLINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ERAVACYCLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ERAVACYCLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ERAVACYCLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TIGECYCLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TIGECYCLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL TIGECYCLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INPATIENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INPATIENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INPATIENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL OUTPATIENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL OUTPATIENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL OUTPATIENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RESEARCH AND ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RESEARCH AND ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RESEARCH AND ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 78. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 80. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 81. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 82. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 83. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 84. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 85. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 86. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 87. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 89. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 105. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 107. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 108. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 109. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 110. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 111. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 112. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 113. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 116. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 117. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 118. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 126. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 127. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 128. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 129. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 130. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 131. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 135. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 136. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 137. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 138. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 139. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 140. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 144. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 145. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 146. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 147. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 148. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 149. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 160. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 162. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 163. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 164. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 165. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 166. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 167. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 168. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 169. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 171. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 172. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 173. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 174. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 175. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 176. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 177. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 179. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 180. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 181. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 182. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 183. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 184. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 185. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 186. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 187. CHINA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 189. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 190. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 191. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 192. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 193. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 194. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 195. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 198. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 199. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 200. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 201. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 202. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 203. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 204. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. JAPAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 207. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 208. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 209. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 210. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 211. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 212. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 213. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. INDIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 217. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 218. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 219. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 220. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 221. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 222. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. GERMANY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 225. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 226. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 227. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 230. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 231. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 234. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 235. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 236. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 237. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 238. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 239. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 240. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 241. AUSTRALIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 243. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 244. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 245. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 246. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 247. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 248. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 249. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 250. FRANCE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 251. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 252. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 253. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 254. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 255. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 256. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 257. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 258. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 259. SOUTH KOREA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 261. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 262. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 263. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 264. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 265. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 266. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 267. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 268. ITALY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 271. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 272. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 273. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 274. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 275. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 276. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. CANADA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 280. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2017-2032 (USD MILLION)
TABLE 281. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2017-2032 (USD MILLION)
TABLE 282. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2017-2032 (USD MILLION)
TABLE 283. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 284. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. BRAZIL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TAB

Companies Mentioned

  • AbbVie Inc.
  • Aridis Pharmaceuticals Inc.
  • Armata Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Cardinal Health, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Debiopharm SA
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Innovation Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Melinta Therapeutics LLC
  • Merck & Co., Inc.
  • Nabriva Therapeutics GMBH
  • Novartis AG
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • R-Biopharm AG
  • Shionogi Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries ltd
  • Theravance Biopharma, Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.34 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.28 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Methicillin-resistant Staphylococcus Aureus Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Methicillin-resistant Staphylococcus Aureus Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2026 - Product Image

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Global Strategic Business Report - Product Image

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Global Strategic Business Report

  • Report
  • 218 Pages
  • Global
From
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Report 2026 - Product Image

Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Vancomycin Market - Global Forecast 2026-2032 - Product Image

Vancomycin Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From

About the MRSA Drug Market

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to many antibiotics. As a result, it is a major cause of infections in hospitals and other healthcare settings. To combat this, the MRSA drug market has developed a range of treatments, including antibiotics, antiseptics, and vaccines. These drugs are designed to target the bacteria and reduce the risk of infection. The MRSA drug market is highly competitive, with a range of companies offering different treatments. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. These companies are constantly developing new treatments to combat the spread of MRSA and other infectious diseases. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.